| 1 | no | 176,229 |
| 2 | p=not | 25 |
| 3 | reported.no | 4 |
| 4 | placebo.no | 3 |
| 5 | 5/1000 | 2 |
| 6 | corticosteroids.no | 2 |
| 7 | p=no | 2 |
| 8 | *no | 1 |
| 9 | -2.20g/dl | 1 |
| 10 | //www.who.int/en/ | 1 |
| 11 | 1175.2 | 1 |
| 12 | 12/325 | 1 |
| 13 | 16.5-fold | 1 |
| 14 | 50-450 | 1 |
| 15 | 8,580 | 1 |
| 16 | 9-135 | 1 |
| 17 | 9.30/1000 | 1 |
| 18 | active-mean | 1 |
| 19 | age-level | 1 |
| 20 | anti-cirrhosis | 1 |
| 21 | antigpc-3-chemoprotective | 1 |
| 22 | between-cadence | 1 |
| 23 | between-context | 1 |
| 24 | between-office | 1 |
| 25 | bidimensionally | 1 |
| 26 | clinically/medically | 1 |
| 27 | compared.no | 1 |
| 28 | ctca-detected | 1 |
| 29 | discussion- | 1 |
| 30 | ego-diminishing | 1 |
| 31 | fatality.the | 1 |
| 32 | il-3/tnfα | 1 |
| 33 | inter-segmental | 1 |
| 34 | low.four | 1 |
| 35 | n-duopropenide | 1 |
| 36 | nitrogen-corrected | 1 |
| 37 | pdhs | 1 |
| 38 | pik3ca-mutated | 1 |
| 39 | punjabi/urdu | 1 |
| 40 | qol-profiles | 1 |
| 41 | respectively-a | 1 |
| 42 | risperidone.other | 1 |
| 43 | schizophrenia.no | 1 |
| 44 | small-modest | 1 |
| 45 | sports'-were | 1 |
| 46 | statistically-significantly | 1 |
| 47 | subcellularly | 1 |
| 48 | thermogalvanic | 1 |
| 49 | tu-100-related | 1 |
| 50 | variable.the | 1 |
| 51 | venganoor | 1 |
| 52 | ≤25-μm | 1 |
| 1 | *no | 1 |
| 2 | -2.20g/dl | 1 |
| 3 | //www.who.int/en/ | 1 |
| 4 | 1175.2 | 1 |
| 5 | 12/325 | 1 |
| 6 | 16.5-fold | 1 |
| 7 | 5/1000 | 2 |
| 8 | 50-450 | 1 |
| 9 | 8,580 | 1 |
| 10 | 9-135 | 1 |
| 11 | 9.30/1000 | 1 |
| 12 | active-mean | 1 |
| 13 | age-level | 1 |
| 14 | anti-cirrhosis | 1 |
| 15 | antigpc-3-chemoprotective | 1 |
| 16 | between-cadence | 1 |
| 17 | between-context | 1 |
| 18 | between-office | 1 |
| 19 | bidimensionally | 1 |
| 20 | clinically/medically | 1 |
| 21 | compared.no | 1 |
| 22 | corticosteroids.no | 2 |
| 23 | ctca-detected | 1 |
| 24 | discussion- | 1 |
| 25 | ego-diminishing | 1 |
| 26 | fatality.the | 1 |
| 27 | il-3/tnfα | 1 |
| 28 | inter-segmental | 1 |
| 29 | low.four | 1 |
| 30 | n-duopropenide | 1 |
| 31 | nitrogen-corrected | 1 |
| 32 | no | 176,229 |
| 33 | p=no | 2 |
| 34 | p=not | 25 |
| 35 | pdhs | 1 |
| 36 | pik3ca-mutated | 1 |
| 37 | placebo.no | 3 |
| 38 | punjabi/urdu | 1 |
| 39 | qol-profiles | 1 |
| 40 | reported.no | 4 |
| 41 | respectively-a | 1 |
| 42 | risperidone.other | 1 |
| 43 | schizophrenia.no | 1 |
| 44 | small-modest | 1 |
| 45 | sports'-were | 1 |
| 46 | statistically-significantly | 1 |
| 47 | subcellularly | 1 |
| 48 | thermogalvanic | 1 |
| 49 | tu-100-related | 1 |
| 50 | variable.the | 1 |
| 51 | venganoor | 1 |
| 52 | ≤25-μm | 1 |
| 1 | discussion- | 1 |
| 2 | //www.who.int/en/ | 1 |
| 3 | 9.30/1000 | 1 |
| 4 | 5/1000 | 2 |
| 5 | 50-450 | 1 |
| 6 | 8,580 | 1 |
| 7 | 1175.2 | 1 |
| 8 | 12/325 | 1 |
| 9 | 9-135 | 1 |
| 10 | respectively-a | 1 |
| 11 | thermogalvanic | 1 |
| 12 | tu-100-related | 1 |
| 13 | pik3ca-mutated | 1 |
| 14 | nitrogen-corrected | 1 |
| 15 | ctca-detected | 1 |
| 16 | 16.5-fold | 1 |
| 17 | between-office | 1 |
| 18 | between-cadence | 1 |
| 19 | n-duopropenide | 1 |
| 20 | variable.the | 1 |
| 21 | fatality.the | 1 |
| 22 | sports'-were | 1 |
| 23 | antigpc-3-chemoprotective | 1 |
| 24 | ego-diminishing | 1 |
| 25 | inter-segmental | 1 |
| 26 | -2.20g/dl | 1 |
| 27 | age-level | 1 |
| 28 | ≤25-μm | 1 |
| 29 | active-mean | 1 |
| 30 | no | 176,229 |
| 31 | *no | 1 |
| 32 | schizophrenia.no | 1 |
| 33 | compared.no | 1 |
| 34 | reported.no | 4 |
| 35 | placebo.no | 3 |
| 36 | corticosteroids.no | 2 |
| 37 | p=no | 2 |
| 38 | risperidone.other | 1 |
| 39 | venganoor | 1 |
| 40 | low.four | 1 |
| 41 | qol-profiles | 1 |
| 42 | pdhs | 1 |
| 43 | anti-cirrhosis | 1 |
| 44 | p=not | 25 |
| 45 | small-modest | 1 |
| 46 | between-context | 1 |
| 47 | punjabi/urdu | 1 |
| 48 | clinically/medically | 1 |
| 49 | bidimensionally | 1 |
| 50 | subcellularly | 1 |
| 51 | statistically-significantly | 1 |
| 52 | il-3/tnfα | 1 |